Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDAAA Post-Marketing Requirements Growing As Commitments Decline

Executive Summary

Safety studies imposed under FDA Amendments Act authorities are a growing portion of sponsors’ post-approval study burden, while post-marketing commitments are declining, according to the latest FDA annual report on the status of post-marketing requirements and commitments.

You may also be interested in...

FDA’s Guidance Document To-Do List Grows

Since releasing its annual guidance agenda in December, FDA has added a number of guidances to its development agenda.

Throwing The Postmarketing Switch: On- and Off-Schedule Commitments And Requirements

FDA Sets One-Month Target For Post-Marketing Requirement Discussions In Final Guidance

Industry wanted FDA to impose a detailed set of internal requirements on itself before imposing PMRs, but in final guidance on the subject the agency does not do so.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts